Previous Close | 0.7851 |
Open | 0.7800 |
Bid | 0.7553 x 1400 |
Ask | 0.7600 x 1400 |
Day's Range | 0.7513 - 0.7800 |
52 Week Range | 0.5500 - 2.2000 |
Volume | |
Avg. Volume | 164,283 |
Market Cap | 36.421M |
Beta (5Y Monthly) | -0.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4040 |
Earnings Date | Nov 09, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for AIM
OCALA, Fla., August 15, 2022--AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement regarding the outcome of a hearing in the Delaware Court of Chancery concerning a motion for a temporary restraining order ("TRO") sought by activist shareholder Jonathan Jorgl:
AIM CEO Thomas K. Equels AIM CEO Thomas K. Equels – On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Capital position expected to fund company through end of 2023 OCALA, Fla., Aug. 15, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on
Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions Daniel Peterson, MD, the Sierra Internal Medicine in Incline Village, Nev. Daniel Peterson, MD, the Sierra Internal Medicine in Incline Village, Nev. Charles Lapp, MD, the Hunter-Hopkins Center in Charlotte, N.C. Charles Lapp, MD, the Hunter-Hopkins Center in Charlotte, N.C. OCALA, Fla., July 28, 2